Losartan, with an IUPAC name of 2-n-butyl-4-chloro-5-hydroxymethyl-1-((2¢-(1H-tetrazol-5yl)(biphenyl-4yl)methyl)-imidazole potassium salt (Scheme 1), is a strong antihypertensive agent, non-peptide, and exerts its action by a specific blockade of angiotensin II receptors. [1] [2] [3] It develops a gradual and longlasting effect as antihypertensive, becoming a new alternative to this frequent chronic-disease treatment. Several methods have been described for the determination of a losartan potassium drug substance in tablets. These methods employ techniques such as high-performance liquid chromatography (HPLC), supercritical fluid chromatography (SFC), capillary electrophoresis (CE) 4 and high-performance thin-layer chromatography (HPTLC). 5 In biological fluids, the active principle as well as its metabolites have been determined by HPLC, UV detection, 6 fluorescence detection, 7 and liquid chromatography electrospray ionization tandem mass spectrometry. 8 Triamterene (2,4,7-triamino-6-phenylpteridine) (Scheme 1) is a mild diuretic belonging to the potassium-saving family, which acts directly on distal tubular cells to diminish the release of potassium ions and to avoid the reassertion of chloride ions as a result. By itself, it is relatively inefficient as a hypertensive, so it is usually associated with some other, more potent diuretic (e.g. a thiazide or anthranilic acid derivative). This association has a synergistic effect by which the diuretic and hypertensive actions of the components are mutually enhanced. 9 The concomitant use of potassium-sparing diuretics and angiotensin II receptor blockers (ARBs) may increase the risk of severe hyperkalemia. The mechanism has additive potassium-sparing effects. Both agents individually have been associated with hyperkalemia. Patients with diabetes, heart failure, dehydration, or renal insufficiency, or who are taking more than 25 mg/day of spironolactone may have a greater risk of developing severe hyperkalemia from this combination. 10 Thus, in order to gather enough information for the diagnosis of hyperkalemia, developing a simple method for the determination of losartan and triamterene in biological fluids is necessary.
First measurements of triamterene have been directly made in pharmaceutical preparations by perchloric acid titrations.
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be an efficient electroanalytical technique for the determination of sub-nanomolar levels of a wide range of drugs that have an interfacial adsorptive character onto the working electrode surface. It usually involves a simple accumulation step, and most of the excipients used do not interfere in the subsequent determination of drugs. 18 The technique is easy to use, and saves of both time and costs.
According to our knowledge, there is only one reported paper for the determination of triamterene by the electrochemical method based on potentiometry 19 with high limit of detection. Therefore, there has been no report concerning the single and sequential determination of both drugs by voltammetric methods. The proposed method is a highly sensitive, simple, fast and accurate method with lower detection limits for the determination of losartan and triamterene in tablets and urine. The method is based on the cathodic adsorptive stripping of the Cu(II)-losartan complex and a direct reduction of triamterene on a hanging mercury drop electrode (HMDE). Then, the preconcentrated species were analyzed by cathodic stripping square-wave voltammetry.
Experimental

Chemicals
All of the chemicals were of analytical grade, and were purchased from Merck (Darmstadt, Germany), unless stated otherwise. Doubly distilled water was used throughout. Losartan and triamterene were purchased from Iran-Hormone and Sobhan Pharmaceutical Companies (Tehran, Iran), respectively.
A stock solution (100.0 mg mL -1
) of Cu(II) was prepared by dissolving 0.0100 g of copper metal in 0.1 mol L -1 HCl and diluted with water in a 100-ml volumetric flask. A 1.0 ¥ 10 -3 mol L -1 losartan solution was prepared daily by dissolving 0.0461 g of losartan potassium salt (99%) in water, and the solution was diluted to 100 ml with water in a 100-ml volumetric flask. The solution was kept in a refrigerator at 4˚C and in the dark. More dilute solutions were prepared by serial dilution with water. A 1.0 ¥ 10 -4 mol L -1 triamterene solution was prepared daily by dissolving 0.0025 g of triamterene (99.5%) in alkaline water, and the solution was diluted to 100 ml with water in a 100-ml volumetric flask. The solution was kept in a refrigerator at 4˚C in the dark. More dilute solutions were prepared by serial dilution with water.
Losartan tablets (Iran-Hormone Pharmaceutical Co., Iran, labeled 25 mg losartan per tablet) and triamterene tablets (Sobhan Pharmaceutical Co., Iran, labeled 50 mg triamterene per tablet) were purchased from the Red Cross drug store in Isfahan.
Britton-Robinson (B-R) buffers (0.1 mol L -1 in phosphate, acetate and borate) in the pH range of 2 -9 were used throughout.
Apparatus
Voltammetric measurements were carried out using a Metrohm instrument, Model 797 VA, comp trace with stand three-electrodes containing HMDE as a working electrode, a platinum rode as an auxiliary electrode and an Ag/AgCl (3.0 mol L -1 KCl) reference electrode. A Pentium IV (2.0 MHz) computer controlled all of the settings and data processing.
A pH-meter (Corning, Model 140) with a double-junction glass electrode was used to check the pH of the solutions.
Preparation of real samples
For the preparation of tablet solutions, five tablets were mixed and powdered. A portion of the powder containing approximately 76 mg of losartan and/or 200 mg of triamterene was accurately weighted and then dissolved in 20 ml of water. After mixing completely, the mixture was filtered with ordinary filtration paper. Then, the filtered solution was transferred into a 1000-ml volumetric flask, and the solution was diluted to the mark with water.
Urine samples were filtered through a cellulose acetate filter (0.2 mm pore size, Supelco) and collected in dark glass bottles previously cleaned with hydrochloric acid and washed with deionized water. The samples were stored in darkness at 4˚C until the analyses were performed.
Procedure
For the determination of losartan and triamterene, 10 ml of the supporting electrolyte solution (B-R buffer at pH 3.0) containing 30.0 ng mL -1 copper(II) was pipetted into the electrochemical cell. The solution was purged with nitrogen gas for 3 min. An adsorption potential of -0.30 V vs. Ag/AgCl was applied to a fresh HMDE, and adsorption was carried out in a stirred solution (1800 rpm) for a period of 80 s. Then, a square-wave stripping voltammogram was recorded from +0.15 to -1.20 V with a potential scan rate of 400 mV s -1 and a voltage amplitude of 20 mV. After the background voltammogram was obtained (Ipb), aliquots of the sample solution containing a certain concentration of losartan and/or triamterene were introduced into the cell while maintaining the nitrogen atmosphere above the solution and mixing for 20 s. Then, the above mentioned procedure was repeated to obtain square-wave voltammogram to obtain the sample peak currents (Ips). The difference current (Ips -Ipb) was considered as a net signal (DIp). All of the data were obtained at room temperature. Calibration graphs were prepared by plotting the net peak currents versus the losartan and triamterene concentrations.
Results and Discussion
Adsorptive characteristics of the Cu(II)-losartan complex and triamterene
Preliminary experiments were carried out to identify the general features that characterize the behavior of the Cu(II)-losartan complex and triamterene systems on the mercury electrode. Figure 1 As illustrated in Fig. 1 , the sensitivity of the losartan reduction peak current increased due to the addition of Cu(II) to the solution. This response increased when an accumulation time preceded the potential scan. This reduction current increased linearly with increasing Cu(II) concentrations. With respect to the facts that the losartan reduction current increased due to the addition of Cu(II) to the solution and the dependence of peak current on the accumulation time, it can be concluded that the Cu(II)-losartan complex was adsorbed on the surface of the electrode during accumulation. As is obvious in Fig. 1 , the triamterene reduction peak current and the peak potential did not depend on the Cu(II) concentration. This phenomenon shows that triamterene did not form any complex with Cu(II). Due to the dependency of the appropriate peak on accumulation time, triamterene was also adsorbed on the surface of the electrode.
Electrochemical studies Cyclic voltammetry studies.
The cyclic voltammetric responses of a HMDE in B-R buffer solution (pH 3.0) and in the presence of 30.0 ng mL -1 Cu(II) with different concentrations of losartan are shown in Fig. 2 . As is shown, there are two cathodic and two anodic peaks due to the reduction and oxidation of the Cu(II) and Cu(II)-losartan complex. Similarly, the cyclic voltammetric responses of different concentrations of triamterene in a universal buffer solution (pH 3.0) on HMDE show only two reduction peaks (Fig. 3) . This behavior matches with a totally irreversible system.
In order to prove adsorption of the (losartan)m-Cu(II) complex and triamterene on the surface of HMDE, cyclic voltammograms of the related species at different scan rates (20.0 to 250.0 mV s -1 ) were recorded, and the cathodic peak currents versus scan rate were plotted. The relationship between the peak currents and the scan rates were linear (r 2 = 0.9923, 0.9926) with equations of Ip = 0.09(±0.01)u + 7.85(±0.95) and Ip = 0.17(±0.02)u + 3.17(±0.82) (n = 3) for the losartan-Cu(II) complex and triamterene, respectively.
These results demonstrate an adsorption process during the faradic reaction. 
Determination of the number of electron transfers (n). Cu(II)-losartan complex:
To determine the number of electrons in the reduction of the complex, according to previous reports, 24 direct current polarography has been used. As calculated, Cu(II) and losartan (L) produces only a single complex of CuL2:
The equilibrium constant is
By considering Eq. (3) into Eq. (5), we obtain 
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Resulting from inserting Eq. (6) to Eq. (7), we can obtain Eq.
From a plot of E1/2 complex vs. log[L] one can determine the number of electron transfers (n). Equation (8) shows that such a plot should have a slope of -4.6RT/nF. With the aid of Eq. (8), a straight line with an equation of E1/2 complex = -0.056(±0.005)¥ log[L] -0.208(±0.012) (r 2 = 0.9820) was obtained for three replicate measurements. Consequently, we obtained n = 2.09, which is close to the expected value (n = 2.0). Triamterene. To determine the number of protons and electrons in the reduction of triamterene (T), direct current polarography has been used. The half reduction peak potential of the triamterene is proportional to the pH of the solution. Therefore, we can consider the following equations for the reduction process:
THy + zH + + n2e -ae AE THy+z.
In the absence of migration, the rate of mass transfer is proportional to the concentration gradient at the electrode surface. 25 Therefore, the overall Nernst equation can be written as follows:
A similar equation can be written for the reduction of traimterene in two steps, as follows:
By plotting E via log((il -i)/i), a linear plot with a slope of 2.3RT/nF can be observed. Thus, the number of electron transfers in each reducing step can be calculated.
With the aid of Eqs. (14) and (15) (14) and (15) measurements) . Consequently, we obtained y = 2.15 and z = 2.04, which are close to the expected value (n = 2.0). Tafel plot analyses. The cathodic Tafel plots of the Cu(II)-losartan complex (300 nmol L -1 ) was plotted using the CV data of Fig. 2 on the surface of DME, and also for triamterene (150 nmol L -1 ). By a linear-regression fit of the cathodic Tafel plots, the cathodic Tafel slope was determined. The average cathodic Tafel slopes are -3.82 V dec -1 for Cu(II)-losartan complex and -28.45 and -9.82 V dec -1 for two-step reduction peaks of triamterene, respectively. Thus, the corresponding apparent transfer coefficients can be calculated from the Tafel slopes. The calculated transfer coefficients are 0.11 for the reduction peak of Cu(II)-losartan and 0.84 and 0.29 for the two-step reduction peaks of triamterene, respectively.
The electrochemical reaction process for losartan in the presence of Cu(II) ion on HMDE electrode can be suggested to be as follows: 
Determination of losartan and triamterene
Effect of operational parameters. In order to optimize the procedure for the determination of losartan and triamterene, we studied the effect of chemical and instrumental factors, including the pH, Cu(II) concentration, accumulation potential, accumulation time, and scan rate on the peak currents for enhanced sensitivity and selectivity. The influence of the pH on the cathodic stripping peak currents of losartan-Cu(II) and triamterene was studied in the pH range of 1.7 -11.0. It was found that at pH 3.0, the peak currents of losartan and triamterene were at their relatively high values. Thus, pH 3.0 was adopted for further studies. However, by increasing the pH (>3.0), the peak current of losartan decreased due to decreasing the stability of the losartan-Cu(II) complex. A similar behavior was observed for triamterene at pH > 6.0 due to a reduction of the proton gradient concentration.
The effect of the Cu(II) concentration on the peak currents of losartan and triamterene was also studied in the range of 0 -50 ng mL -1 . The obtained results showed that the cathodic peak currents of the Cu(II)-losartan complex increased with increasing the Cu(II) concentration up to 25 ng mL -1 , but it then leveled off at higher concentrations. As mentioned above, the Cu(II) concentration does not have any effect on the triamterene peak current. Therefore, an optimum Cu(II) concentration of 30 ng mL -1 was selected for further experiments. The effect of the accumulation potential on the peak currents of losartan and triamterene was examined over the range of 0.20 to -0.70 V. As can be seen in Fig. 4 , in the potential range from 0.20 to 0.00 V, the peak currents of the two species increased. In addition, due to having a higher sensitivity for losartan and triamterene in the accumulation potential of -0.30 V, an accumulation potential of -0.30 V was selected for determination of the two species.
The cathodic peak current in square-wave voltammetry versus the accumulation time for losartan and triamterene with the optimum pH and Cu(II) concentration was studied in the range of 0 -120 s. At first, the peak current increased linearly with the accumulation time, indicating that before adsorptive equilibrium is reached, the longer was the accumulation time, the more species were adsorbed and thus the peak currents became larger. However, after an 80 s period of the accumulation time, the peak currents tended to level off for both losartan and triamterene, illustrating that adsorptive equilibrium was achieved. According to the above results, an accumulation time of 80 s was selected for further studies.
The influence of the potential scan rate on the reduction peak currents of the losartan-Cu(II) complex and triamterene were also studied under the optimized conditions containing 200.0 nmol L -1 losartan, 50.0 nmol L -1 triamterene in the present of 30.0 ng mL -1 Cu(II), pH 3.0, an accumulation potential of -0.30 V and an accumulation time of 80 s (Fig. 5) . The results showed that the peak currents for losartan and triamterene were dependent on the scan rate in the range of 0.07 to 0.30 V s -1 , and those were leveled off. Therefore, a scan rate of 0.40 V s -1 was selected for further studies.
Accordingly, the established optimal operational parameters of the proposed square-wave adsorptive cathodic stripping voltammetric procedure were, B-R buffer at pH 3.0 as a supporting electrolyte, a Cu(II) concentration of 30.0 ng mL -1 , an accumulation potential of -0.30 V (versus Ag/AgCl), an accumulation time of 80 s and a scan rate of 0.40 V s -1 .
Method validation
Validating the analytical method is a procedure by which it is established that the performance characteristics of the method meet the requirements for the extended analytical applications. This was examined via an evaluation of the linear dynamic range, limit of detection (LOD), repeatability, precision and selectivity. The limits of detection (defined as the amount of analytes that increases the response to 3Sb (Sb is the standard deviation of the blank solution)), were 9.7, 0.3 nmol L -1 for losartan and triamterene, respectively. The relative standard deviations (n = 5) for 100.0 nmol L -1 losartan and 10.0 nmol L -1 triamterene were 5.5%.
Interference studies
Interfering species that may exist in pharmaceutical formulations and biological fluids were investigated concerning the adsorptive stripping voltammetric determination of losartan and triamterene by the addition of appropriate species to a solution containing 30.0 ng mL -1 of Cu(II), 200.0 nmol L -1 losartan and 50.0 nmol L -1 triamterene using the optimized conditions. The tolerance limit was defined as the concentrations that gives an error of £5% in the determination of losartan and/or triamterene. The interference study was carried out for 21 compounds at several molar ratios over losartan and triamterene on the measured analytical concentrations. The results show no significant interference from recipients. It is concluded that the method is free from interferences of foreign species.
Applicability of the proposed method
The proposed square-wave adsorptive cathodic stripping voltammetric procedure was successfully applied to the determination of losartan and triamterene in pharmaceutical formulations (tablets) and human urine without interference from excipients. The recovery of losartan and triamterene in those real samples, based on the average of four replicate measurements, is reported in Tables 1 and 2 . The accuracy of the proposed procedure was evaluated by applying the standard addition method. 
